All News
CAR-T effective B cell depletion preserving plasma cell function @rheumnow #EULAR2024 https://t.co/mYmwC2cV6e
Peter Nash drpnash ( View Tweet)
« CAR T cells can change the therapeutic scenario: a short treatment for a prolonged efficacy » says G. Schett
Are we finally looking at the « visionary scenario »?
@RheumNow #EULAR2024 https://t.co/tzfDormeIl
Aurelie Najm AurelieRheumo ( View Tweet)
@Janetbirdope @RheumNow #EULAR2024 JAK-i Debate
@drdavidliew (NOT in support of regulation)
- is the signal real? Query about replicability & data came from N. America. Not reflected on real-world data of enriched cohorts
- is the warning justified?
- are there unintended consequences?
@RheumNow https://t.co/TXUf90fqwN
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Asking the quintessential Australian question at #EULAR24 by @drdavidliew - does the ORAL surveillance study for JAKi *truly* pass the pub test?
@eular_org @Janetbirdope @RheumNow
What does #MedTwitter think? https://t.co/bqwPU8XX5S
Links:
Benjamin Sutu benjaminsutu ( View Tweet)
Pt with LN, endocarditis, pericarditis, arthritis, rash failed CTX, MMF, BEL, and SOC. She is 1000 days post CAR-T cell. Off immunomodulating drugs. #SLE in remission clinically and serologically. - Dr G Schett #EULAR24 @RheumNow https://t.co/3vdMtO6VWI
TheDaoIndex KDAO2011 ( View Tweet)
#EULAR2024 JAK-i Debate.
@Janetbirdope [Pro Regulatory Safety Measures]
- to do no harm esp since there are other alternatives
- supported by RCT
- although JAK-i have different structures, data from individual RCT + LTE showed similar rates of malignancy & MACE @RheumNow https://t.co/jQKQmHE9Fg
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Areas to consider in difficult to manage PsA and research agenda #EULAR2024 Chandran V @RheumNow https://t.co/sp4tkAivLa
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Significant proportion of patients in PsA do not achieve remission across the domains. This can be due to disease heterogeneity, domain differences, comorbidities. There is a need to study the use of combination ts and bDMARDs. Difficult to Manage PsA session #EULAR2024 Ribeiro,… https://t.co/Wt3jgtIR9N https://t.co/VzCApikqek
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Join us later for a some very exciting pieces of translational science across a AIRDs.
All these abstracts sharing one thing in common: tissue, tissue, tissue!
16:30-18:00 Room A8.2
@RheumNow #EULAR2024 https://t.co/HrHP5tmHDD
Aurelie Najm AurelieRheumo ( View Tweet)
Grappa - distinguish D2T from complex to manage - objective signs of inflammation imaging - US or MRI not lab markers @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
#EULAR2024 Eular Debate Showdown between @Janetbirdope vs @drdavidliew
Topic: can observational study debunk RCT?
This stemmed from Oral Surveillance = an increased risk of malignany & MACE with tofacitinib compared with TNF-i. Regulatories extrapolated to all JAK-i @RheumNow https://t.co/hg6xJZDHiA
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
The great debate on JAKi risk and special warnings
And who better than @RheumNow to keep score between @Janetbirdope & @drdavidliew
Get the popcorn ready 🍿
#EULAR2024 https://t.co/z50Ob8q0i0
Aurelie Najm AurelieRheumo ( View Tweet)
almost half PsA patients have 3 pr more co-morbidities and 67% of those surveyed do not think rheumos should not manage them - when did we stop being physicians ? @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
« difficult to treat PsA » how mich combination obesity, non-inflammatory MSK pain, fibromyalgia and depression making assessment tricky and risk of rattling through therapies fast! @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
Dr. D Aletaha defines The #EULARManifesto, "It is about patient centeredness-- improving quality of care, advocating for patients, timely access to specialists, pushing R&D innovation, integrating technology to make sure every patient gets the care they need." @rheumnow #EULAR24
TheDaoIndex KDAO2011 ( View Tweet)
🌎 Global disparities in steroid prescribing in #SLE
💊 HCQ assoc with decreased steroid use
📈 Other contributing factors may be prevalence, severity & phenotype of disease, plus access to DMARDs & biologics
📍SLE poster tour 15:30 TODAY
#EULAR2024
Abs #POS0013
@RheumNow https://t.co/7pL8kpeqOs
Mrinalini Dey DrMiniDey ( View Tweet)
LBA0001 (2024)
EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH GIANT CELL ARTERITIS (SELECT-GCA): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
- looking good, nice results @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
LONG-TERM EFFICACY TOCILIZUMAB AFTER ULTRA-SHORT GC TO TREAT GCA: 3 Yr FOLLOW-UP OF THE GUSTO TRIAL
3 day GC pulse immediate 12 mths Toci 85% drug free remission at 4 yrs! @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
RISK OF PsA IN PATIENTS WITH PsO UNDERGOING bDMARDs GLOBAL POPULATION STUDY (TRINETX)
870,000 PsO pts without PsA treated with bDMARDS - Il12/23i and Il23i. 30-37% lower PsA developed than comparators @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
OP0031 (2024)
COMPARATIVE ANALYSIS OF TNF INHIBITORS AND IL17 INHIBITORS IN PSORIATIC ARTHRITIS: EXPLORING CARDIOVASCULAR OUTCOMES signif absolute risk difference 3 % ischaemic heart disease 2 % heart failure TNFi vs IL17i @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)